发明申请
US20060199978A1 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
审中-公开
具有5-羟色胺5-ht17受体拮抗剂活性和毒蕈碱m4受体激动剂活性的化合物及其在治疗精神病中的应用
- 专利标题： Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders
- 专利标题（中）： 具有5-羟色胺5-ht17受体拮抗剂活性和毒蕈碱m4受体激动剂活性的化合物及其在治疗精神病中的应用
-
申请号： US10551138申请日： 2004-03-29
-
公开(公告)号： US20060199978A1公开(公告)日： 2006-09-07
- 发明人: Dimitrios Lizos , Clare McKerchar , John Murphy , Yasuyuki Shiigi , Colin Suckling , Hiroshi Yasumatsu , Shen-ze Zhou , Judith Pratt , Brian Morris
- 申请人： Dimitrios Lizos , Clare McKerchar , John Murphy , Yasuyuki Shiigi , Colin Suckling , Hiroshi Yasumatsu , Shen-ze Zhou , Judith Pratt , Brian Morris
- 优先权： GB030737.7 20030329; GB0307366.5 20030329
- 国际申请： PCT/GB04/01367 WO 20040329
- 主分类号： A61K31/155
- IPC分类号： A61K31/155 ; C07C251/16
摘要：
The present invention relates to novel treatments for schizophrenia, based on the concept of identifying agents capable of selectively binding to the serotonin 5-HT7 and muscarinic M4 receptors and the use of such compounds in treating schizophrenia. The present invention also relates to novel amidine compounds for treating schizophrenia, a method of manufacturing such compounds, pharmaceutical formulations comprising said compounds, as well as medical uses and methods of treatment using said compounds.
信息查询
